Skip to main content

Table 4 Circulating concentrations of osteoprotegerin and breast cancer risk by age at diagnosis: EPIC cohort breast cancer nested case-control study

From: Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort

 

Tertiles

    

1

2

3

    

Cut points (ng/mL)

<0.18

0.18 - <0.22

≥0.22

p trend a

RRlog2 b

p het c

p het d

Age at diagnosis

 <50 yearse

  ER+/PR+

   Cases/controls

82/70

25/35

13/15

    

   RR (95% CI)

Ref.

0.48 (0.23-0.98)

0.53 (0.17-1.69)

0.14

0.48 (0.18-1.28)

  

  ER+

   Cases/controls

99/87

27/40

17/16

    

   RR (95% CI)

Ref.

0.49 (0.25-0.96)

0.79 (0.30-2.09)

0.32

0.64 (0.26-1.54)

  

 ≥50 years

  ER+/PR+

   Cases/controls

260/242

272/273

277/294

    

   RR (95% CI)

Ref.

0.90 (0.69-1.18)

0.86 (0.64-1.16)

0.47

0.89 (0.65-1.22)

0.02

0.53

  ER+

       

   Cases/controls

460/423

492/504

527/552

    

   RR (95% CI)

Ref.

0.87 (0.71-1.06)

0.85 (0.68-1.06)

0.24

0.87 (0.68-1.10)

0.02

0.72

  ER–/PR–

       

   Cases/controls

58/71

71/90

95/63

    

   RR (95% CI)

Ref.

1.15 (0.65-2.02)

2.54 (1.35-4.77)

0.02

2.21 (1.11-4.40)

 

0.30

  ER–

       

   Cases/controls

101/119

103/112

123/96

    

   RR (95% CI)

Ref.

1.21 (0.77-1.92)

1.90 (1.17-3.09)

0.04

1.76 (1.03-3.01)

 

0.62

  1. Conditional logistic regression models adjusted for ages at menarche (≤12, 13, 14, ≥15, missing), menopause (<44, 44-47, 48-50, 51-52, 53-54, ≥55, missing), first full-term pregnancy (no FTP, <25, 25-30, ≥30, missing), number of full-term pregnancies (0, 1, 2, ≥3, missing), and BMI (kg/m2, continuous)
  2. a p trend based on log2-transformed continuous variable
  3. bRR for a one-unit change in log2-transformed OPG
  4. c p heterogeneity comparing ER+/PR+ to ER–/PR– and ER+ to ER– subtypes, based on RRlog2
  5. d p heterogeneity comparing age at diagnosis <50 to 50+ years based on RRlog2
  6. eAge at diagnosis results limited to ER+/PR+ and ER+ cases given n = 34 ER–/PR– cases; n = 59 ER– cases in this subgroup
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us